CRIS

SEC source: 0001209191-20-016227 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common stock · 750,000 shares

Expires 2030-03-01

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on March 2, 2021 and as to an additional 6.25% of the original shares each successive quarter and until March 2, 2024.

SEC source: 0001209191-20-004918 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,158

F2 · kind: This transaction was effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

SEC source: 0001209191-20-004918 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,252

F1 · shares: Shares were sold pursuant to a "sell to cover" arrangement to satisfy minimum statutory tax withholding obligations related to a vesting of a service-based restricted stock award granted on January 22, 2018.

SEC source: 0001209191-19-049285 · doc4.xml · derivative · entry 1

Steinkrauss William · CIK 0001772403 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common stock · 125,000 shares

Expires 2029-09-10

F1 · derivative.exercise_date: This option vests as to 25% of the original 125,000 shares underlying the award on the first anniversary of the date of grant and as to an additional 6.25% of the original shares underlying the award at the end of each successive three month period thereafter, subject to continued service.

SEC source: 0001209191-19-032974 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,115,871

Underlying: Common Stock · 1,115,871 shares

Expires 2029-01-20

F1 · date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

SEC source: 0001209191-19-032970 · doc4.xml · derivative · entry 1

Martell Robert · CIK 0001529922 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,996

Underlying: Common stock · 386,996 shares

Expires 2029-01-20

F1 · date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

SEC source: 0001209191-19-005357 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,639

F1 · kind: These transactions were effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.17, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005354 · doc4.xml · nonDerivative · entry 1

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,089

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005355 · doc4.xml · nonDerivative · entry 2

Martell Robert · CIK 0001529922 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,027

F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005355 · doc4.xml · nonDerivative · entry 1

Martell Robert · CIK 0001529922 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,527

F1 · kind: Shares were withheld by the Company to satisfy minimum statutory withholding requirements related to a vesting of a service-based restricted stock award granted on January 22, 2018.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005357 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,733

F1 · kind: These transactions were effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005352 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,819

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005351 · doc4.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,200

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.095, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005350 · doc4.xml · nonDerivative · entry 1

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,121

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-004996 · doc4.xml · derivative · entry 1

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-01-20

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company.

SEC source: 0001209191-19-004995 · doc4.xml · derivative · entry 1

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-01-20

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company.

SEC source: 0001209191-19-004993 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-01-20

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company.

SEC source: 0001209191-19-004985 · doc4.xml · derivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-01-20

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company.

SEC source: 0001209191-18-052464 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common stock · 750,000 shares

Expires 2028-09-25

F1 · derivative.exercise_date: This option vests as to 25% of the shares on September 26, 2019 and as to an additional 6.25% of the original shares each successive three month period through and until September 26, 2022.

SEC source: 0001209191-18-035586 · doc4.xml · derivative · entry 1

Martell Robert · CIK 0001529922 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,000

Underlying: Common stock · 303,000 shares

Expires 2028-05-31

F1 · derivative.exercise_date: This option vests as to 25% of the original shares on June 1, 2019 and as to an additional 6.25% of the original shares underlying the award each successive three month period through and until June 1, 2022, subject to continued service.

SEC source: 0001209191-18-030875 · doc4.xml · derivative · entry 1

Tuck David · CIK 0001664707 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 535,000

Underlying: Common stock · 535,000 shares

Expires 2028-01-21

F1 · date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

SEC source: 0001209191-18-030871 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · COO & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 825,000

Underlying: Common stock · 825,000 shares

Expires 2028-01-21

F1 · date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

SEC source: 0001209191-18-030864 · doc4.xml · derivative · entry 1

Fattaey Ali Ph.D. · CIK 0001570026 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 825,000

Underlying: Common stock · 825,000 shares

Expires 2028-01-21

F1 · date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

SEC source: 0001209191-18-005147 · doc4.xml · nonDerivative · entry 1

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,945

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

F2 · balance_after: Represents 37,945 shares of unrestricted common stock and 185,000 shares of restricted common stock.

SEC source: 0001209191-18-005152 · doc4.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

SEC source: 0001209191-18-005165 · doc4.xml · nonDerivative · entry 1

Martell Robert · CIK 0001529922 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

SEC source: 0001209191-18-005148 · doc4.xml · nonDerivative · entry 1

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,607

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

F2 · balance_after: Represents 29,607 shares of unrestricted common stock and 185,000 shares of restricted common stock.

SEC source: 0001209191-18-005150 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,596

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

F2 · balance_after: Represents 51,596 shares of unrestricted common stock and 185,000 shares of restricted common stock.

SEC source: 0001209191-18-005136 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,011

F1 · shares: This award is in the form of restricted common stock. The award vests as to 25% of the underlying shares on the first anniversary of the date of grant and as to an additional 25% of the underlying shares annually thereafter.

F2 · balance_after: Represents 5,761 shares of unrestricted common stock acquired under Curis, Inc.'s Amended and Restated 2010 Employee Stock Purchase Plan and 206,250 shares of restricted common stock.

SEC source: 0001209191-18-005142 · doc4.xml · nonDerivative · entry 1

Tuck David · CIK 0001664707 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,424

F1 · shares: This award is in the form of restricted common stock. The award vests as to 25% of the underlying shares on the first anniversary of the date of grant and as to an additional 25% of the underlying shares annually thereafter.

F2 · balance_after: Represents 35,674 shares of unrestricted common stock acquired under Curis, Inc.'s Amended and Restated 2010 Employee Stock Purchase Plan and 133,750 shares of restricted common stock.

SEC source: 0001209191-18-005133 · doc4.xml · nonDerivative · entry 1

Fattaey Ali Ph.D. · CIK 0001570026 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,140

F1 · shares: This award is in the form of restricted common stock. The award vests as to 25% of the underlying shares on the first anniversary of the date of grant and as to an additional 25% of the underlying shares annually thereafter.

F2 · balance_after: Represents 115,890 shares of unrestricted common stock and 206,250 shares of restricted common stock.

SEC source: 0001209191-17-061106 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,596

F1 · price: These shares were purchased between $0.975-$0.984/share. The Company will provide, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-17-060795 · doc4.xml · nonDerivative · entry 1

Fattaey Ali Ph.D. · CIK 0001570026 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,890

F1 · price: These shares were purchased between $0.97-$1.11/share. The Company will provide, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-17-037269 · doc4.xml · derivative · entry 5

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2017-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037269 · doc4.xml · derivative · entry 4

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2017-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037269 · doc4.xml · nonDerivative · entry 3

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,945

F1 · kind: The reporting person acquired 2,807 shares of common stock on "net exercise" of options that expire on June 6, 2017. The transaction was the net of: (1) an exercise of an aggregate of 15,000 options to purchase common stock; and (2) a tender of 12,193 shares of common stock for payment of the exercise price, using the closing stock price on May 31, 2017 of $1.71.

SEC source: 0001209191-17-037269 · doc4.xml · nonDerivative · entry 2

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037269 · doc4.xml · nonDerivative · entry 1

GREENACRE MARTYN D · CIK 0001209727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037263 · doc4.xml · derivative · entry 5

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2017-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037263 · doc4.xml · derivative · entry 4

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2017-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037263 · doc4.xml · nonDerivative · entry 3

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,607

F1 · kind: The reporting person acquired 2,807 shares of common stock on "net exercise" of options that expire on June 6, 2017. The transaction was the net of: (1) an exercise of an aggregate of 15,000 options to purchase common stock; and (2) a tender of 12,193 shares of common stock for payment of the exercise price, using the closing stock price on May 31, 2017 of $1.71.

SEC source: 0001209191-17-037263 · doc4.xml · nonDerivative · entry 2

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-037263 · doc4.xml · nonDerivative · entry 1

KAITIN KENNETH I · CIK 0001271823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 3

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 50,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares.

F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached.

F5 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 3

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 50,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 2

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 66,176

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares.

F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached.

F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 2

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 66,176

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 1

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 96,276

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares.

F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached.

F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 1

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 96,276

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

SEC source: 0001209191-17-029242 · doc4.xml · nonDerivative · entry 3

MCNAB JAMES R · CIK 0001190126 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By JR & MW McNab Operating LP

Disclosed balance after: 126,276

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.26 to $2.39, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.